Search research articles
Contact Us
Filters
Showing results (491-500 of 532) with videos related to
Page
of 54
Sort By:
Breast Cancer Research and Treatment
|
April 23, 2019
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa
Catherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Circulation
|
October 21, 2020
2020 International Consensus on First Aid Science With Treatment Recommendations
Eunice M Singletary, David A Zideman, Jason C Bendall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Priya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
Sandra M Swain, Gong Tang, Charles E Geyer, et al.
The Lancet. Oncology
|
October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
André Robidoux, Gong Tang, Priya Rastogi, et al.
Obesity (Silver Spring, Md.)
|
December 22, 2016
Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial
Shelby Sullivan, James M Swain, George Woodman, et al.
JAMA Oncology
|
March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials
Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
The Lancet. Oncology
|
August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology
|
December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Eleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Page
of 54
Search research articles
Search
Showing results (491-500 of 532) with videos related to
Sort By:
Page
of 54
Breast Cancer Research and Treatment
|
April 23, 2019
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa
Catherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Circulation
|
October 21, 2020
2020 International Consensus on First Aid Science With Treatment Recommendations
Eunice M Singletary, David A Zideman, Jason C Bendall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Priya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
Sandra M Swain, Gong Tang, Charles E Geyer, et al.
The Lancet. Oncology
|
October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
André Robidoux, Gong Tang, Priya Rastogi, et al.
Obesity (Silver Spring, Md.)
|
December 22, 2016
Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial
Shelby Sullivan, James M Swain, George Woodman, et al.
JAMA Oncology
|
March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials
Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
The Lancet. Oncology
|
August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology
|
December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Eleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Page
of 54